ValiRx (LSE:VAL) COGS-to-Revenue : 0.00 (As of Dec. 2024)

View and export this data going back to 2000. Start your Free Trial

What is ValiRx COGS-to-Revenue?

ValiRx's Cost of Goods Sold for the six months ended in Dec. 2024 was £0.00 Mil. Its Revenue for the six months ended in Dec. 2024 was £0.05 Mil.

ValiRx's COGS to Revenue for the six months ended in Dec. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. ValiRx's Gross Margin % for the six months ended in Dec. 2024 was N/A%.

ValiRx COGS-to-Revenue Historical Data

The historical data trend for ValiRx's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx COGS-to-Revenue Chart

ValiRx Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.20

ValiRx Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	0.20	-	-

ValiRx COGS-to-Revenue Calculation

ValiRx's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0.05
	=	0.00

ValiRx's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0.05
	=	0.00

ValiRx (LSE:VAL) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

ValiRx's Gross Margin % for the six months ended in Dec. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0.05
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

ValiRx COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of ValiRx's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

ValiRx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

D6 Thane Road, MediCity Nottingham, Nottingham, GBR, NG90 6BH

Website

https://www.valirx.com

ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in their different stages of development.